Development of SBS-226, a MOR agonist / DOR antagonist, for OUD

$3,957,359UG3FY2024DANIH

Sparian Biosciences, Inc., New York City NY

Investigators

Jeffrey Reichcontact

View original record on NIH RePORTER →